COYA
Coya Therapeutics Inc

1,125
Mkt Cap
$101.27M
Volume
110,275.00
52W High
$8.29
52W Low
$3.94
PE Ratio
-4.39
COYA Fundamentals
Price
$4.84
Prev Close
$4.42
Open
$4.43
50D MA
$5.32
Beta
0.91
Avg. Volume
337,125.65
EPS (Annual)
-$0.9765
P/B
2.97
Rev/Employee
$444,257.63
Loading...
Loading...
News
all
press releases
Coya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·10d ago
News Placeholder
More News
News Placeholder
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital reissued a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday...
MarketBeat·19d ago
News Placeholder
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to...
Business Wire·20d ago
News Placeholder
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·1mo ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital reissued a "buy" rating and issued a $15.00 price target on shares of Coya Therapeutics in a research report on Monday...
MarketBeat·1mo ago
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital restated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·2mo ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·2mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.